News | April 01, 2023
Alniche Lifesciences expands footprints in respiratory care
The upcoming portfolio of respiratory products aims to provide effective solutions for a range of respiratory conditions
The upcoming portfolio of respiratory products aims to provide effective solutions for a range of respiratory conditions
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
This is the third major regulatory milestone for the vaccine candidate following acceptance of regulatory submissions in Europe and Japan
Themis Medicare’s VIRALEX is an effective and safe drug for management of mild to moderate COVID and other acute viral respiratory infections.
RSV is the most common viral cause of respiratory tract infections in newborns, young children, older adults, or the immunocompromised
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
New inhalers would have near-zero Global Warming Potential propellant
The interim analysis showed that the MVC-COV1901 vaccine has a good safety profile and elicits promising neutralising antibody titres
RT-PCR test detects and differentiates SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus
Subscribe To Our Newsletter & Stay Updated
